Launch of PCR genotyping assay portfolio to detect COVID-19 variants

Paris, France and Camberley, UK – 2 February 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces the launch of a new and innovative portfolio of assays (under the brand name SNPsig®) to aid the diagnosis of the new variants of SARS-CoV-2. http://novacyt.com/wp-content/uploads/2021/02/Novacyt-Variants-launch-02.02.21-ENGLISH.pdf

Visit Page

Full Year 2020 Trading Update

Paris, France and Camberley, UK – 29 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an unaudited trading update for the year ended 31 December 2020. http://novacyt.com/wp-content/uploads/2021/01/Novacyt-Trading-Update-29.01.2021-ENGLISH.pdf

Visit Page

Holdings in Company

Paris, France and Camberley, UK – 26 January 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it was notified on 26 January 2021 that, as at 25 January 2021 BlackRock Inc.’s holding in the Company on a voting and capital basis is 3.02% (2,132,372 shares). http://novacyt.com/wp-content/uploads/2021/01/Novacyt-BlackRock-holdings-26.01.2021-ENGLISH.pdf

Visit Page